How come nobody discuses new fda regulatory trial endpoints that are being allowed on ongoing cell therapy clinical trials.
No need for placebo control if it looks like obvious efficacy. Use of real world data. Its actually a game changer in the business because clinical trials will be much cheaper. Anyway one of you smart guys should elaborate on the new guidance coming forward
Cheers friends
How come nobody discuses new fda regulatory trial endpoints that...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
-0.020(1.88%) |
Mkt cap ! $1.187B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.03 | $3.428M | 3.281M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 43055 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 85631 | 29 |
View Market Depth
| Last trade - 13.23pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |